Literature DB >> 11675038

Effects of CP-99, 994, a tachykinin NK(1) receptor antagonist, on abdominal afferent vagal activity in ferrets: evidence for involvement of NK(1) and 5-HT(3) receptors.

M Minami1, T Endo, H Yokota, T Ogawa, M Nemoto, N Hamaue, M Hirafuji, M Yoshioka, A Nagahisa, P L Andrews.   

Abstract

The effect of CP-99, 994, a tachykinin NK(1) receptor antagonist, on abdominal vagal afferent nerve activity in the ferret was investigated. Substance P (1 microg/kg, i.v.) increased vagal afferent activity by 449.0+/-51.9% and this was reduced to 145.9+/-5.7% (p<0.01) by pre-treatment with CP-99, 994 (1 mg/kg, i.v.), and to 149.5+/-1.5% (p<0.001) by granisetron (1 mg/kg, i.v.), a 5-HT(3) receptor antagonist. In addition, the increase in vagal nerve activity induced by 5-HT (25 microg/kg, i.v., 552.0+/-57.0% increase from pre-injection level) was significantly reduced (401.3+/-10.6% increase from pre-injection level, p<0.05) by CP-99, 994 (100 microg/kg, i.v.). These results provide evidence for an involvement of peripheral NK(1) and 5-HT(3) receptors in substance P-induced vagal afferent activation. While the functional consequences (if any) of such peripheral effects were not investigated, they could contribute either directly (e.g. by blockade of receptors on vagal afferents) or indirectly (e.g. modulation of 5-HT release or reduction of local inflammatory response) to the antiemetic effects of CP-99, 994 against cisplatin and other emetic agents acting primarily via the vagus.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11675038     DOI: 10.1016/s0014-2999(01)01297-3

Source DB:  PubMed          Journal:  Eur J Pharmacol        ISSN: 0014-2999            Impact factor:   4.432


  17 in total

1.  The antiemetic 5-HT3 receptor antagonist Palonosetron inhibits substance P-mediated responses in vitro and in vivo.

Authors:  Camilo Rojas; Ying Li; Jie Zhang; Marigo Stathis; Jesse Alt; Ajit G Thomas; Sergio Cantoreggi; Silvia Sebastiani; Claudio Pietra; Barbara S Slusher
Journal:  J Pharmacol Exp Ther       Date:  2010-08-19       Impact factor: 4.030

2.  Interactions of metoclopramide and ergotamine with human 5-HT(3A) receptors and human 5-HT reuptake carriers.

Authors:  Jan Walkembach; Michael Brüss; Bernd W Urban; Martin Barann
Journal:  Br J Pharmacol       Date:  2005-10       Impact factor: 8.739

Review 3.  Current pharmacotherapy for chemotherapy-induced nausea and vomiting in cancer patients.

Authors:  Michelle C Janelsins; Mohamedtaki A Tejani; Charles Kamen; Anita R Peoples; Karen M Mustian; Gary R Morrow
Journal:  Expert Opin Pharmacother       Date:  2013-04       Impact factor: 3.889

4.  Utilization of the least shrew as a rapid and selective screening model for the antiemetic potential and brain penetration of substance P and NK1 receptor antagonists.

Authors:  Nissar A Darmani; Yaozhi Wang; Joseph Abad; Andrew P Ray; Gerald R Thrush; Juan Ramirez
Journal:  Brain Res       Date:  2008-04-09       Impact factor: 3.252

5.  Ablation of least shrew central neurokinin NK1 receptors reduces GR73632-induced vomiting.

Authors:  Andrew P Ray; Seetha Chebolu; Juan Ramirez; Nissar A Darmani
Journal:  Behav Neurosci       Date:  2009-06       Impact factor: 1.912

Review 6.  Signals for nausea and emesis: Implications for models of upper gastrointestinal diseases.

Authors:  Paul L R Andrews; Charles C Horn
Journal:  Auton Neurosci       Date:  2006-03-23       Impact factor: 3.145

Review 7.  Pharmacological management of chemotherapy-induced nausea and vomiting: focus on recent developments.

Authors:  Rudolph M Navari
Journal:  Drugs       Date:  2009       Impact factor: 9.546

Review 8.  Neurokinin NK1 and NK3 receptors as targets for drugs to treat gastrointestinal motility disorders and pain.

Authors:  Gareth J Sanger
Journal:  Br J Pharmacol       Date:  2004-03-15       Impact factor: 8.739

9.  Intracellular emetic signaling evoked by the L-type Ca2+ channel agonist FPL64176 in the least shrew (Cryptotis parva).

Authors:  Weixia Zhong; Seetha Chebolu; Nissar A Darmani
Journal:  Eur J Pharmacol       Date:  2018-06-30       Impact factor: 4.432

10.  Recent advances in pharmacotherapy of chemotherapy-induced nausea and vomiting.

Authors:  Prasan R Bhandari
Journal:  J Adv Pharm Technol Res       Date:  2012-10
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.